Clinical trial · Interventional
Bevacizumab and Vasoconstriction
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hypertension. In patients treated with bevacizumab hypertension had an overall incidence up to 32%. The etiology of hypertension caused by treatment with angiogenesis inhibitors is unclear. Objective: To study if arterial bevacizumab infusion causes acute vasoconstriction using plethysmography in healthy volunteers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Hypertension | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Bevacizumab
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- Fore-arm vasomotor response to administered bevacizumab, expressed as percentage change in forearm blood flow ratio
- timeFrame
- Infusion of bevacizumab during 6 minutes
Secondary outcomes (1)
- measure
- Correlation between VEGF concentrations in plasma and the vasoconstrictive response to bevacizumab
- timeFrame
- Infusion of bevacizumab during 6 minutes
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Male 18-50 years old * normal results of glucose, lipids and creatinine * informed consent Exclusion Criteria: * History of abuse of drugs or alcohol * History of malignant disease * First degree relatives with a history of cancer before the age of 50 * First degree relatives with a history of premature cardiovascular disease * Current use of medication * Clinical evidence of cardiac of pulmonary disease * Hypertension ( systolic\>140mmHg, diastolic \>90mmHg) * Diabetes mellitus * smoking * a history of thombosis or a family history of recurrent thrombosis * abnormality on ECG
References
Publications (0)
Data not yet available